Organisation paid for research Program year 2025 Source: CMS Open Payments

Forcare Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$4,663,714

969 payments

Through program year 2025, Forcare Clinical Research is reported as receiving $4,663,714 in research payments, across 969 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $290,032 275
2024 Research $1,216,021 444
2023 Research $2,582,633 169
2022 Research $411,853 45
2021 Research $141,422 20
2020 Research $20,454 13
2019 Research $1,299 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $2,083,280 5 payments
  2. Incyte Corporation $1,088,300 842 payments
  3. Moderna TX, Inc. $789,552 18 payments
  4. AbbVie, Inc. $314,868 36 payments
  5. Biofrontera Bioscience GmbH $140,958 6 payments
  6. Celgene Corporation $99,902 2 payments
  7. Biohaven Pharmaceuticals, Inc. $66,558 13 payments
  8. Pfizer Inc. $32,601 19 payments
  9. GlaxoSmithKline, LLC. $15,193 6 payments
  10. Ucb SA $11,053 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $2,056,456 4 payments
  2. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $789,117 15 payments
  3. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $313,684 282 payments
  4. Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo $246,490 26 payments
  5. A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo $148,993 59 payments
  6. A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa $143,006 75 payments
  7. Ala-Acv-Ct014 $140,958 6 payments
  8. A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo $126,069 55 payments
  9. A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema $83,714 69 payments
  10. BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $71,840 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record